A Second Look: Discussing Point Bio's 177Lu-PNT2002 in mCRPC after recent data presented at ESMO 2022

Executed on:Sep 13, 2022 1:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Arizona Center for Cancer Care

Board-certified radiation oncologist with expertise in the management of breast, prostate and gastrointestinal cancers in a Multispecialty Oncology Group.
Currently manages ~100 patients with prostate cancer with an interest in utilizing new and advanced treatment techniques to minimize side effects
Member of the American Society for Therapeutic Radiology and Oncology, American Brachytherapy Society, American College of Radiology and the Arizona Radiological Society

Interview Goal

This conversation will focus on the standard of care for metastatic castration resistant prostate cancer and the potential of new therapies in development with a specific focus on 177Lu-PNT2002. We will dig into the recent data from the Phase 3 SPLASH study of 177Lu-PNT2002 from Point Biopharma,and how it may compare to Pluvicto with an oncologist who treats mCRPC.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.